Gemzar approved for breast cancer
Executive Summary
Lilly's Gemzar approved for use in combination with Bristol-Myers Squibb's Taxol for first-line treatment of metastatic breast cancer May 19. Clinical studies included in 1labeling show improvement in time to disease progression of 2.3 months over paclitaxel alone (5.2 versus 2.9 months). Overall response rate was 40.8% versus 22.1% for paclitaxel alone. Gemzar is already indicated for first-line non-small cell lung and pancreatic cancer...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.